Methotrexate shows the same efficacy and safety in the real world in all subtypes of JIA as in the controlled trial
Main Authors: | Foedvari I, Wierk A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-09-01
|
Series: | Pediatric Rheumatology Online Journal |
Similar Items
-
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohortsResearch in context
by: Stephanie J.W. Shoop-Worrall, et al.
Published: (2024-02-01) -
The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
by: Joly J, et al.
Published: (2011-09-01) -
Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study
by: Roth J, et al.
Published: (2011-09-01) -
Jia
by: Chong, Clara Jia Jie
Published: (2017) -
Correction: Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.
by: PLOS ONE Staff
Published: (2016-01-01)